Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

50.86
-0.4900-0.95%
Post-market: 51.050.1900+0.37%17:22 EST
Volume:758.57K
Turnover:38.67M
Market Cap:2.92B
PE:-148.90
High:51.88
Open:51.48
Low:50.19
Close:51.35
52wk High:57.65
52wk Low:29.16
Shares:57.34M
Float Shares:48.90M
Volume Ratio:1.11
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3416
EPS(LYR):1.32
ROE:-1.86%
ROA:1.52%
PB:2.78
PE(LYR):38.53

Loading ...

Earning Preview: Supernus Pharmaceuticals Q4 revenue is expected to increase by 25.33%, and institutional views are bullish

Earnings Agent
·
Feb 17

Jefferies Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
Feb 19

Supernus Pharmaceuticals Inc. published an update to their financial calendar

Reuters
·
Feb 13

Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative

Simply Wall St.
·
Feb 12

India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR

MT Newswires Live
·
Feb 05

Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
Jan 28

Crawford & Company Sets $475,000 Salary and New Incentives for US Operations CEO

Reuters
·
Jan 16

Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says

MT Newswires Live
·
Jan 08

Supernus Pharmaceuticals SVP Frank Mottola Reports Sale of Common Shares

Reuters
·
Dec 23, 2025

Supernus Pharmaceuticals SVP Padmanabh Bhatt Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

Supernus Pharmaceuticals on Pace for Longest Winning Streak Since July 2024 -- Data Talk

Dow Jones
·
Dec 20, 2025

Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada

MT Newswires Live
·
Dec 09, 2025

Supernus Pharmaceuticals to Present at Bank of America Securities CNS Therapeutics Virtual Conference

Reuters
·
Dec 04, 2025

Supernus Pharmaceuticals to Join Piper Sandler Annual Healthcare Conference

Reuters
·
Nov 22, 2025

Supernus Pharmaceuticals (SUPN): Assessing Valuation After Q3 Revenue Growth and Raised Guidance Despite Net Loss

Simply Wall St.
·
Nov 16, 2025

Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed?

Simply Wall St.
·
Nov 10, 2025

Supernus Pharmaceuticals (SUPN): Evaluating Valuation After Strong Q3 Growth, Margin Pressure, and Updated 2025 Outlook

Simply Wall St.
·
Nov 09, 2025

Supernus Pharmaceuticals Down Nearly 18%, On Track for Largest Percent Decrease Since November 2019 -- Data Talk

Dow Jones
·
Nov 06, 2025

Stock Track | Supernus Pharmaceuticals Plummets 21.58% as Q3 Earnings Show Significant Loss Despite Revenue Beat

Stock Track
·
Nov 05, 2025

Stock Track | Supernus Pharmaceuticals Plunges 12.25% Pre-market Following Q3 Loss Despite Revenue Beat

Stock Track
·
Nov 05, 2025